Amlan International Launches AGP Alternative, Varium™

Many chickens feeding in a poultry production barn.

Amlan International Launches AGP Alternative, Varium™


CHICAGO, IL— Amlan International announces the launch of Varium™, a new non-antibiotic formulated product that acts like an antibiotic growth promoter (AGP) for poultry. In clinical studies Varium promotes broiler growth equivalent to antibiotics by reducing the level of pathogens and harmful biotoxins that damage the intestinal lining, stimulating early immune function, and strengthening the intestinal barrier function.

“Research studies conducted with leading poultry collaborators in the U.S. showed that Varium consistently achieved growth performance equivalent to commercial AGPs and also reduced the effects of bacteria-associated enteric disease,” said Dr. Ron Cravens, President, Amlan International.

As the global poultry production community continues to shift to a no antibiotics ever approach in light of consumer and regulatory pressures, such as the FDA’s Veterinary Feed Directive, interest in AGP alternatives that address bird intestinal health while enhancing performance is growing.

Biotoxins produced by microorganisms such as Clostridium perfringens, E. coli, and Salmonella sp. damage the intestinal barrier, which reduces overall gut health and function thereby diverting energy from weight gain. Decreased gut function can also cause birds to suffer from lower feed conversion and increased mortality. By focusing on maintaining a healthy intestinal environment, producers are able to maximize the efficiency of their nutritional program.

“Varium has been shown to lower Clostridium perfringens induced Necrotic Enteritis lesion scores, improve feed conversion, reduce mortality and support weight gain,” said Cravens. “In fact, in clinical trials, Varium provided a ROI of 3:1 or higher by improving feed conversion and decreasing mortality.”

Varium is currently approved for use in Bolivia, Malaysia, Peru, the Philippines and Thailand, and is waiting registration approval in multiple other countries in South America, the Middle East and the Asia-Pacific region. For more information visit



About Amlan International

A wholly owned subsidiary of the Oil-Dri Corporation of America (NYSE: ODC), Amlan International helps producers increase animal productivity by developing products that enhance intestinal health and function. Since its inception in 2007, Amlan has grown its product offering across the intestinal health and AGP-alternative market, driven largely by the research conducted in its laboratory campus in Vernon Hills, IL. In 2014, the company’s global reach expanded with the opening of China operations in Shenzhen. Further information on Amlan International is available at Amlan–Productivity for Life.